Frailty, Socioeconomics, and Specialist Access Drive Overactive Bladder Care Disparities - Ekene Enemchukwu
Ekene Enemchukwu
Ruchika Talwar interviews Ekene Enemchukwu about her Medicare-based study examining disparities in overactive bladder (OAB) treatment, particularly focusing on the utilization of beta-3 agonists versus anticholinergic medications.
Making Sense of Advanced Technologies to Integrate into your OAB Program "Presentation" - Kari Bailey, David Sussman & Neil Kocher
At the 2024 LUGPA annual meeting, Kari Bailey, David Sussman, and Neil Kocher discuss advanced overactive bladder therapies, highlighting the shift toward earlier use of neuromodulation and tibial nerve stimulation.